Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acurx Pharmaceuticals, Inc. (ACXP)

3.54   0.29 (8.92%) 03-24 16:00
Open: 3.31 Pre. Close: 3.25
High: 3.55 Low: 3.28
Volume: 2,887 Market Cap: 41(M)

Technical analysis

as of: 2023-03-24 4:23:46 PM
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.54     One year: 5.3
Support: Support1: 3.33    Support2: 3
Resistance: Resistance1: 3.89    Resistance2: 4.54
Pivot: 3.37
Moving Average: MA(5): 3.24     MA(20): 3.38
MA(100): 3.53     MA(250): 3.5
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 38.2     %D(3): 25
RSI: RSI(14): 54.4
52-week: High: 4.84  Low: 2.32
Average Vol(K): 3-Month: 35 (K)  10-Days: 32 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ACXP ] has closed below upper band by 26.6%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.55 - 3.56 3.56 - 3.57
Low: 3.25 - 3.26 3.26 - 3.28
Close: 3.51 - 3.54 3.54 - 3.56

Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Headline News

Thu, 23 Mar 2023
New to The Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support - Yahoo Finance

Fri, 17 Mar 2023
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call Transcript - Yahoo Finance

Mon, 06 Mar 2023
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year ... - PR Newswire

Thu, 02 Mar 2023
Factbox-Elon Musk's missed deadlines for FDA approval of Neuralink brain-chip trials - Yahoo News

Thu, 16 Feb 2023
Tenon Medical Inc (TNON) has fallen 12.39% Thursday In Premarket Trading - InvestorsObserver

Tue, 14 Feb 2023
Acurx is Setting a High Bar for New Treatments in C. diff - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 12 (M)
Shares Float 8 (M)
% Held by Insiders 21.1 (%)
% Held by Institutions 11.9 (%)
Shares Short 25 (K)
Shares Short P.Month 21 (K)

Stock Financials

EPS -0.99
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.62
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -66.8
Return on Equity (ttm) -122.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -8 (M)
Levered Free Cash Flow -3 (M)

Stock Valuations

PE Ratio -3.62
PEG Ratio 0
Price to Book value 5.61
Price to Sales 0
Price to Cash Flow -5.45

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.